Nuvation Bio (NYSE:NUVB) Insider Sells $251,000.00 in Stock

Nuvation Bio Inc. (NYSE:NUVB) insider Dongfang Liu sold 50,000 shares of the firm’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $5.02, for a total transaction of $251,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at $90,360. This trade represents a 73.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nuvation Bio Price Performance

Nuvation Bio stock opened at $5.06 on Friday. The firm has a 50-day moving average price of $4.83 and a 200-day moving average price of $5.86. The firm has a market capitalization of $1.76 billion, a PE ratio of -8.42 and a beta of 1.60. The company has a current ratio of 6.95, a quick ratio of 6.81 and a debt-to-equity ratio of 0.15. Nuvation Bio Inc. has a 12-month low of $1.57 and a 12-month high of $9.75.

Nuvation Bio (NYSE:NUVB) last released its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The firm had revenue of $41.87 million during the quarter, compared to analyst estimates of $36.82 million. As a group, equities research analysts forecast that Nuvation Bio Inc. will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Nuvation Bio

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Nuvation Bio by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company’s stock valued at $139,378,000 after purchasing an additional 101,011 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Nuvation Bio by 52.4% in the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after purchasing an additional 1,298,131 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Nuvation Bio by 19.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock valued at $12,276,000 after purchasing an additional 551,508 shares in the last quarter. Aisling Capital Management LP raised its holdings in shares of Nuvation Bio by 16.5% in the 3rd quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock valued at $10,954,000 after purchasing an additional 419,650 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Nuvation Bio by 852.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after purchasing an additional 2,424,109 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NUVB shares. Truist Financial set a $13.00 price objective on shares of Nuvation Bio in a report on Tuesday, January 27th. UBS Group decreased their price objective on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, March 3rd. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Thursday, April 16th. HC Wainwright decreased their price objective on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a report on Monday, January 12th. Finally, Royal Bank Of Canada lifted their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.63.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.